On March 14, 2019, China MAH Certification and Conversion Forum and Medical Technology Trading Conference was held in Hangzhou Dajiangdong Industrial Cluster (Hangzhou Economic and Technological Development Zone), Wang Yongfang, deputy director of Hangzhou Economic and Technological Development Zone Management Committee, Zhejiang Province Xu Runlong, director of the Drug Administration, and other relevant leaders attended the meeting. As the first batch of member units, Paradise Silicon Valley Asset Management Group participated in the unveiling ceremony of the Zhejiang Pharmaceutical Listing License Holder (MAH) Conversion Platform. The platform is the first non-profit alliance organization in the province and even the whole country dedicated to drug life cycle management such as drug research and development, production, sales and post-marketing quality inspection management. The first batch of members of the platform has 31, including 10 pharmaceutical research and development institutions such as Hangzhou Heze Pharmaceutical Technology Co., Ltd. and Hangzhou Tiger Medical Technology Co., Ltd., Zhejiang Kangenbei Pharmaceutical Co., Ltd. and Hangzhou Minsheng Pharmaceutical Co., Ltd. The company has 10 large pharmaceutical companies, including financial and insurance institutions, law firms and medical data service companies.

Paradise Silicon Valley has always been deeply involved in the medical and medical field. It has participated in supporting the listing of many pharmaceutical companies, industrial mergers and acquisitions, and has a solid foundation for cooperation with many listed companies and related companies in the industry. In the future, the company will give full play to the professional advantages of asset management in the conversion platform for Zhejiang drug listing license holders, and utilize the rich experience and resources accumulated in the field of pharmaceutical investment over the years to innovate drugs, generic drugs and biopharmaceuticals in the platform. Comprehensive investment and development of various types of drugs, CMO commissioned production management system, drug quality life monitoring system, drug circulation and transfer, pharmaceutical M&A and other aspects provide comprehensive support and strategic cooperation, and develop together with the platform to help Zhejiang Province drugs Reform and development of health medicine.